Living with OCD often comes with a sense that nobody quite knows what works. The exhausting cycle of unwanted thoughts, followed by rituals or avoidance, can feel too particular for general advice.
In 2023 an international group of psychiatrists published an updated set of treatment guidelines addressing that question. Now in their third version, the guidelines reviewed decades of research to establish which treatments genuinely help. Cognitive behavioural therapy, specifically exposure and response prevention, is among the clearest recommendations, with medication indicated in some cases.
ERP works by gradually helping a person face the thoughts and situations that trigger anxiety, while resisting the ritual or avoidance that usually follows. Over time the brain has the opportunity to learn that the feared outcome does not arrive, and the urgency of the compulsion begins to fade.
The value of guidelines like these is that they do not represent one clinician's opinion. They are an international consensus built on a large body of research, which means the recommended approach is tested and well understood.
OCD is treatable. If you are ready to take a first step, a psychologist experienced in OCD is a good place to start.
What this guideline actually covers
One point of precision first. This paper, Part I of the series, deals with anxiety disorders: panic disorder and agoraphobia, generalised anxiety disorder, social anxiety disorder, specific phobias, and related conditions in children and adolescents such as separation anxiety and selective mutism. It was produced by the World Federation of Societies of Biological Psychiatry. Obsessive-compulsive disorder is covered separately, in another part of the same guideline series. The method behind the recommendations is the same one applied to the OCD guidance: a review of the evidence, followed by expert consensus and a ranking of treatments. The specific figures below relate to anxiety disorders rather than OCD.
How the recommendations were built
A panel of 33 experts from 22 countries worked through 1007 randomised controlled trials. In such a trial, people are assigned at random to receive either a treatment or a comparison, such as a placebo or a different treatment. Randomisation matters because it helps establish whether the treatment is genuinely responsible for improvement, rather than people simply improving over time regardless of what they received.
The panel applied the same strict evaluation standards normally reserved for medications, including when assessing psychotherapy. In practice that meant a psychological treatment needed solid, replicated evidence to earn a strong recommendation. Early or promising findings were not sufficient.
What it found
Two classes of medication emerged as first-line pharmacological options across the anxiety disorders reviewed: SSRIs, or selective serotonin reuptake inhibitors, and SNRIs, serotonin-norepinephrine reuptake inhibitors. These adjust levels of particular brain chemicals, serotonin in the case of SSRIs, and both serotonin and norepinephrine for SNRIs, which are thought to contribute to the regulation of mood and anxiety.
On the psychological side, cognitive behavioural therapy was rated first-line. CBT is a structured, skills-based therapy that targets unhelpful thought patterns and behaviours rather than exploring feelings alone. The panel also set out guidance for people who do not respond to standard options, and identified treatments where the evidence was too weak to support a recommendation in either direction.
Why it matters, and where its limits lie
The value of a document like this lies not in uncovering something new. It lies in working through an enormous and often inconsistent body of research, more than a thousand trials, and converting it into clear, ranked guidance that clinicians anywhere can rely on. That process is considerably more rigorous than any single study and more useful than any individual clinician's judgement.
The document should be read for what it is. The abstract does not report how much people improved on any given treatment, and it does not compare exact success rates between options. It contains no OCD-specific findings, because OCD sits in a different part of the same guideline family. Anyone wanting to know precisely what the evidence says about OCD treatment would need the companion document.
Whatever the diagnosis, guidelines of this kind exist because these conditions are well understood and treatable. If anxiety, intrusive thoughts or compulsions are affecting your life, speaking with a psychologist is a reasonable step.